Anti-Aggregation Peptides for Neurodegenerative Diseases

Migration, Crosslink

📖

Anti-Aggregation Peptides for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-anti-aggregation-pepti

📖 Wiki Page

therapeutic949 wordssynced 2026-04-02

Anti-Aggregation Peptides for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Aggregation Peptides for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Protein Aggregation ([Aβ](/proteins/amyloid-beta), α-Syn, [Tau](/proteins/tau), mHTT)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to Phase I/II</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ALZ-801</td>
<td>Aβ aggregation</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">GV1005</td>
<td>Beta-amyloid</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>[Alpha-synuclein](/proteins/alpha-synuclein)</td>
</tr>
</table>

Anti Aggregation Peptides For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

...

Anti-Aggregation Peptides for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Aggregation Peptides for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Protein Aggregation ([Aβ](/proteins/amyloid-beta), α-Syn, [Tau](/proteins/tau), mHTT)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to Phase I/II</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ALZ-801</td>
<td>Aβ aggregation</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">GV1005</td>
<td>Beta-amyloid</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>[Alpha-synuclein](/proteins/alpha-synuclein)</td>
</tr>
</table>

Anti Aggregation Peptides For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

Anti-aggregation peptides are short amino acid sequences designed to prevent or reverse the misfolding and aggregation of pathogenic proteins in neurodegenerative diseases. These peptides typically work by binding to aggregation-prone regions of target proteins, blocking their self-assembly into toxic oligomers and fibrils. [@amyloid2020]

Mechanism of Action

Anti-aggregation peptides employ several strategies to combat protein aggregation:

Competitive Inhibition: Peptides containing sequences homologous to the aggregation-prone region compete with the full-length protein for self-assembly, forming non-toxic complexes instead.

β-Sheet Breakers: Peptides designed to bind β-sheet-rich aggregates and convert them to non-aggregating α-helical or random coil structures.

chaperone Mimetics: Peptides that mimic molecular chaperone activity, stabilizing the native conformation of proteins.

Oligomer Stabilization: Some peptides bind to early oligomers, stabilizing them into non-toxic forms (rather than blocking aggregation entirely).

Seeds Invalidation: Certain peptides can bind to aggregation seeds (nuclei) and prevent their ability to template further aggregation.

Key Peptide Candidates

Amyloid-β Targeting Peptides

Aβ42 core sequence fragments: Derived from [Aβ](/proteins/amyloid-beta) residues 16-21 (KLVFF) - the core hydrophobic cluster
Aβ40 fragments: Shorter peptides targeting Aβ40 aggregation
Peptide 6C10: Antibodies-peptide conjugate in development
NL(+1)4Y: Modified Aβ fragment with enhanced activity

α-Synuclein Targeting Peptides

α-Syn residues 61-95:包含 NAC (non-Aβ component) region
Peptide αSyn-L1: Peptide targeting α-syn aggregation
ASO-peptide conjugates: Combining antisense oligonucleotides with aggregation-blocking peptides
PBEF (Preplumbagin) derivatives: Non-peptide aggregators

Tau Targeting Peptides

[Tau](/proteins/tau) peptide fragments: Based on tau repeat domain (R3, R4)
PHF6-derived peptides: Targeting PHF6 (VQIVYK) and PHF6* (VQIVIN) sequences
Tau aggregation inhibitor peptides (TAPs): Engineered peptides

Huntingtin Targeting Peptides

Polyglutamine-blocking peptides: Targeting expanded polyQ sequences
[HTT](/proteins/htt-protein) exon 1 fragments: Targeting mutant [HTT](/genes/htt) aggregation
Peptide 1: PolyQ-targeting peptide in preclinical development

Disease-Specific Applications

Alzheimer's Disease

Aβ aggregation inhibitors in clinical trials (e.g., ALZ-801 - oral amyloid inhibitor)
Peptide vaccines targeting Aβ (e.g., ACI-35 for tau)
β-sheet breaker peptides (e.g., iAβ5p, iAβ11p)
Combination approaches with immunotherapy

Parkinson's Disease

α-syn aggregation inhibitors in preclinical development
Small peptides targeting Lewy body formation
Peptide-dendrimer conjugates for enhanced delivery
Targeting post-translational modifications (phosphorylation, nitration)

Huntington's Disease

Polyglutamine expansion blockers
Peptide-based approaches to reduce mutant HTT aggregation
DNA-PKcs inhibitors to reduce HTT phosphorylation
[Autophagy](/entities/autophagy)-inducing peptides

ALS

SOD1 aggregation inhibitors
[C9orf72](/entities/c9orf72) dipeptide repeat (DPR) aggregation blockers
[TDP-43](/proteins/tdp-43) aggregation inhibitors
Combination with antisense oligonucleotides

Clinical Trials

Delivery Methods

Direct Peptide Administration: Subcutaneous, intravenous, or intranasal delivery

Peptide-Dendrimer Conjugates: Enhanced brain penetration

Peptide-Functionalized Nanoparticles: Targeted delivery

Gene Therapy: AAV-mediated expression of anti-aggregation peptides

Cell-Penetrating Peptides: Fusing peptides with CPPs for CNS delivery

Challenges

[Blood-Brain Barrier](/entities/blood-brain-barrier) Penetration: Peptides generally have poor BBB penetration

Stability: Peptides can be rapidly degraded by proteases

Immunogenicity: Risk of immune reactions to exogenous peptides

Delivery: Ensuring sufficient brain concentrations

Specificity: Avoiding interference with normal protein function

Research Directions

Stapled Peptides: Creating stabilized α-helical peptides with improved stability

Cyclized Peptides: Enhancing protease resistance

Peptide-Polymer Conjugates: Improving pharmacokinetics

Blood-Brain Barrier Shuttle: Using receptor-mediated transcytosis

Dual-Targeting Peptides: Simultaneous targeting of multiple proteins

External Links

[PubMed - Anti-Aggregation Peptides](https://pubmed.ncbi.nlm.nih.gov/?term=anti-aggregation+peptides+neurodegeneration)
[Nature - Protein Aggregation Inhibitors](https://www.nature.com/articles/nrd.2017.56)
[ScienceDirect - Peptide Inhibitors](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/peptide-inhibitor)
[NIH - Amyloid Beta Aggregation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952070/)
[Alzheimer's Association - Research](https://www.alz.org/research)

Background

The study of Anti Aggregation Peptides For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[^1] Solomon B, Immunotherapy and aggregation inhibitors for Alzheimer's disease (2020)

[^2] Frydman-Marom A, et al, Targeting amyloid-β with cell-penetrating peptides (2011)

[^3]lander R, et al, α-Synuclein aggregation and modulation of autophagy by peptide inhibitors (2021)

[^4] Nagai Y, et al, Inhibition of polyglutamine fibril formation and neurotoxicity by a peptide corresponding to the expanded polyglutamine repeat (2003)

[^5] Wisén S, et al, Modulation of amyloid-β toxicity through targeting of central nervous system delivery (2022)

[^6] Braun RJ, et al, Tau aggregation inhibitors for Alzheimer's disease: progress and challenges (2022)

[^7] Scherzer-Okljik L, et al, Peptide-based inhibitors of protein aggregation in neurodegenerative diseases (2021)

[^8] Härd T, et al, Amyloid-β peptide antagonists: a structural perspective (2020)

📖 View canonical wiki page →

Related Entities

therapeutics-anti-aggregation-peptides-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-anti-aggregation-peptides-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2394cddf7af0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-anti-aggregation-peptides-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

190

Outgoing

212

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Anti-Aggregation Peptides for Neurodegenerative Diseases

Anti-Aggregation Peptides for Neurodegenerative Diseases

Introduction

Overview

Anti-Aggregation Peptides for Neurodegenerative Diseases

Introduction

Overview

Mechanism of Action

Key Peptide Candidates

Amyloid-β Targeting Peptides

α-Synuclein Targeting Peptides

Tau Targeting Peptides

Huntingtin Targeting Peptides

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

ALS

Clinical Trials

Delivery Methods

Challenges

Research Directions

See Also

External Links

Background

Allen Brain Atlas Resources

References

💬 Discussion